HER2 Support Group Forums - View Single Post

R.B. · 04-13-2008, 04:17 PM

I know nothing about neuropathy. I have no idea if the pathways are the same in chemo and diabetes.

This may or may not be of interest.

RB

Diabetes. 2003 Oct;52(10):2578-85.Click here to read Links
Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy.
Coste TC, Gerbi A, Vague P, Pieroni G, Raccah D.

UPRES EA 2193, Faculte de Medecine Timone, Marseille, France. Thierry.Coste@medecine.univ-mrs.fr

A deficiency in essential fatty acid metabolism has been widely reported in both human and animal diabetes. Fish oil supplementations (n-3 fatty acids), containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), were less effective on diabetic neuropathy than (n-6) fatty acids. This partial effect of (n-3) fatty acids might be attributed to the presence of EPA, a competitor of arachidonic acid, which enhanced the diabetes-induced decrease of this fatty acid in serum and tissues. For determining whether a supplementation with DHA alone could prevent neuropathy in streptozotocin-induced diabetes, diabetic rats were given daily, by gavage, liposomes containing DHA phospholipids, at a dose of 60 mg/kg. Eight weeks of diabetes induced significant decreases in nerve conduction velocity (NCV), nerve blood flow (NBF), and sciatic nerve and erythrocyte (red blood cells [RBCs]) Na,K-ATPase activities. DHA phospholipids totally prevented the decrease in NCV and NBF observed during diabetes when compared with the nonsupplemented diabetic group. DHA phospholipids also prevented the Na,K-ATPase activity decrease in RBC but not in sciatic nerve. Moreover, DHA level in sciatic nerve membranes was correlated with NCV. These results demonstrate a protective effect of daily doses of DHA on experimental diabetic neuropathy. Thus, treatment with DHA phospholipids could be suitable for evaluation in clinical trials.

04-13-2008, 04:17 PM	#7
R.B. Senior Member Join Date: Mar 2006 Posts: 1,843	I know nothing about neuropathy. I have no idea if the pathways are the same in chemo and diabetes. This may or may not be of interest. RB Diabetes. 2003 Oct;52(10):2578-85.Click here to read Links Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy. Coste TC, Gerbi A, Vague P, Pieroni G, Raccah D. UPRES EA 2193, Faculte de Medecine Timone, Marseille, France. Thierry.Coste@medecine.univ-mrs.fr A deficiency in essential fatty acid metabolism has been widely reported in both human and animal diabetes. Fish oil supplementations (n-3 fatty acids), containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), were less effective on diabetic neuropathy than (n-6) fatty acids. This partial effect of (n-3) fatty acids might be attributed to the presence of EPA, a competitor of arachidonic acid, which enhanced the diabetes-induced decrease of this fatty acid in serum and tissues. For determining whether a supplementation with DHA alone could prevent neuropathy in streptozotocin-induced diabetes, diabetic rats were given daily, by gavage, liposomes containing DHA phospholipids, at a dose of 60 mg/kg. Eight weeks of diabetes induced significant decreases in nerve conduction velocity (NCV), nerve blood flow (NBF), and sciatic nerve and erythrocyte (red blood cells [RBCs]) Na,K-ATPase activities. DHA phospholipids totally prevented the decrease in NCV and NBF observed during diabetes when compared with the nonsupplemented diabetic group. DHA phospholipids also prevented the Na,K-ATPase activity decrease in RBC but not in sciatic nerve. Moreover, DHA level in sciatic nerve membranes was correlated with NCV. These results demonstrate a protective effect of daily doses of DHA on experimental diabetic neuropathy. Thus, treatment with DHA phospholipids could be suitable for evaluation in clinical trials.